Related Experiment Video
Updated: May 8, 2026
Synthesis of an In vivo MRI-detectable Apoptosis Probe
Published on: July 31, 2012
Molecular imaging of apoptosis for early prediction of therapy efficiency
Marijke De Saint-Hubert, Matthias Bauwens, Felix M Mottaghy1
1Nuclear Medicine, MUMC+, Maastricht, The Netherlands ; P.O. Box 5800, 6202 AZ Maastricht. Marijke.De.SaintHubert@mumc.nl.
Abstract:
Evasion of apoptosis is one of the hallmarks of cancer and any effective therapy primarily attempts to induce apoptosis. The evaluation of the degree of success of cancer therapy is currently mainly based on clinical and laboratory parameters and in a later stage on tumor shrinkage. However, none of these parameters provide an objective and early analysis of a therapeutic effect. Molecular imaging may provide a tool for this purpose by using not only pathophysiological but also biochemical effects of the therapy. First in the field, FDG-PET has been explored and demonstrated to offer insight in the amount of viable cells, even though false positives are commonly due to the lack of specificity of this particular radiopharmaceutical. More specific markers target the dying cells instead of those remaining alive. Specific apoptosis markers have been developed of which the radiolabeled Annexin A5 is the most intensely studied probe. Site-specific labeling strategies have improved this imaging probe with good results both in pre-clinical studies and in clinical trials, with promises for clinical applications. Caspase sensitive probes, such as the isatines, can also effectively image apoptosis but are limited due to the high background activities. More recent discoveries of small apoptosis sensitive probes, such as (18)F-ML10, are currently being explored. In this review, the most important apoptosis sensitive probes are described from both a pre-clinical and a clinical perspective, highlighting their potential but also their limitations as an early marker for therapeutic success. It seems that apoptosis imaging can help to guide therapy, not by replacing the current methodology but by providing additional and useful information.
Insights
Molecular imaging offers early detection of cancer therapy effectiveness by tracking apoptosis (programmed cell death). Various probes, like Annexin A5 and (18)F-ML10, show promise in guiding treatment decisions.
Area of Science:
- Oncology
- Molecular Imaging
- Biochemistry
Background:
- Cancer evasion of apoptosis is a key challenge; therapies aim to induce it.
- Current therapy evaluation relies on late clinical/imaging markers, lacking early objective analysis.
- Molecular imaging offers a tool to assess therapy's biochemical effects early.
Purpose of the Study:
- To review apoptosis-sensitive molecular imaging probes for early cancer therapy assessment.
- To highlight the potential and limitations of these probes in preclinical and clinical settings.
- To discuss the role of apoptosis imaging in guiding cancer treatment.
Main Methods:
- Review of existing literature on apoptosis imaging probes.
- Discussion of radiolabeled Annexin A5, caspase-sensitive probes (isatines), and small probes ((18)F-ML10).
- Analysis of probe performance in preclinical studies and clinical trials.
Main Results:
- FDG-PET provides insight into viable cells but lacks specificity.
- Radiolabeled Annexin A5 shows promise with improved labeling strategies.
- Caspase-sensitive probes and newer small probes are under investigation with varying success.
Conclusions:
- Apoptosis imaging offers a valuable, objective, and early assessment of cancer therapy response.
- While not replacing current methods, apoptosis imaging provides crucial additional information for treatment guidance.
- Further development of specific apoptosis probes is essential for clinical application.
